Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.

Since its launch, Rezdiffra has made steady commercial progress. In the third quarter, Madrigal's single approved product ...

Previously, Galmed announced the grant of new use patent for a combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH. The new patent extends Aramchol's patent ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

Investing.com - Oppenheimer raised its price target on Madrigal Pharmaceuticals (NASDAQ:MDGL) to $650.00 from $600.00 while maintaining an Outperform rating. The new target represents potential upside ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investing.com -- Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock gained 3.7% on Thursday after the company announced it received a new patent in South Korea for its lead compound Aramchol in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Resmetirom maintained meaningful improvements in MASH ...

Galmed Pharmaceuticals ( ($GLMD) ) has shared an update. On December 4, 2025, Galmed Pharmaceuticals announced the grant of a new use patent in ...